ICAD vs. CODX, TTOO, APYX, PYPD, STIM, ARAY, CLPT, CVRX, TELA, and QIPT
Should you be buying iCAD stock or one of its competitors? The main competitors of iCAD include Co-Diagnostics (CODX), T2 Biosystems (TTOO), Apyx Medical (APYX), PolyPid (PYPD), Neuronetics (STIM), Accuray (ARAY), ClearPoint Neuro (CLPT), CVRx (CVRX), TELA Bio (TELA), and Quipt Home Medical (QIPT). These companies are all part of the "surgical & medical instruments" industry.
iCAD (NASDAQ:ICAD) and Co-Diagnostics (NASDAQ:CODX) are both small-cap computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, media sentiment, institutional ownership, risk, community ranking and analyst recommendations.
In the previous week, iCAD and iCAD both had 3 articles in the media. Co-Diagnostics' average media sentiment score of 0.96 beat iCAD's score of 0.79 indicating that Co-Diagnostics is being referred to more favorably in the news media.
Co-Diagnostics received 45 more outperform votes than iCAD when rated by MarketBeat users. Likewise, 63.34% of users gave Co-Diagnostics an outperform vote while only 62.81% of users gave iCAD an outperform vote.
24.6% of iCAD shares are held by institutional investors. Comparatively, 15.0% of Co-Diagnostics shares are held by institutional investors. 12.0% of iCAD shares are held by company insiders. Comparatively, 2.4% of Co-Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
iCAD has a beta of 1.36, suggesting that its stock price is 36% more volatile than the S&P 500. Comparatively, Co-Diagnostics has a beta of -0.65, suggesting that its stock price is 165% less volatile than the S&P 500.
iCAD has higher revenue and earnings than Co-Diagnostics. iCAD is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.
iCAD has a net margin of -15.20% compared to Co-Diagnostics' net margin of -582.36%. iCAD's return on equity of -14.00% beat Co-Diagnostics' return on equity.
iCAD currently has a consensus target price of $5.00, suggesting a potential upside of 244.83%. Co-Diagnostics has a consensus target price of $2.00, suggesting a potential upside of 90.48%. Given iCAD's higher possible upside, analysts plainly believe iCAD is more favorable than Co-Diagnostics.
Summary
iCAD beats Co-Diagnostics on 10 of the 15 factors compared between the two stocks.
Get iCAD News Delivered to You Automatically
Sign up to receive the latest news and ratings for ICAD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ICAD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
